English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Background  Uridine diphosphate glucuronosyltransferase 1 family polypeptide A1 ( UGT1A1 ) is a predictive biomarker for the side-effects of irinotecan chemotherapy, which reduces the volume of tumors harboring  UGT1A1  polymorphisms. We aimed to determine whether  UGT1A1  polymorphisms can predict progression-free survival in patients with local cervical cancer treated with irinotecan chemotherapy.    Methods  We retrospectively analyzed the data of 51 patients with cervical cancer treated at a single institution between 2010 and 2015. All patients were diagnosed with 2009 International Federation of Gynecology and Obstetrics (FIGO) stage IB1, IB2, IIA, or IIB squamous cell carcinoma, underwent radical hysterectomy, and received irinotecan chemotherapy as neoadjuvant and/or adjuvant treatment. All patients were examined for irinotecan side effects using  UGT1A1  tests. Conditional inference tree and survival analyses were performed considering the FIGO stage, age, the  UGT1A1  status, and the number of metastatic lymph nodes to determine primary factors associated with progression-free survival.    Results  The tree-structured survival model determined high recurrence-risk factors related to progression-free survival. The most relevant factor was ≥2 metastatic lymph nodes ( p  = 0.004). The second most relevant factor was  UGT1A1  genotype ( p  = 0.024). Among patients with ≤1 metastatic lymph node, those with  UGT1A1  polymorphisms benefited from irinotecan chemotherapy and demonstrated significantly longer progression-free survival ( p  = 0.020) than those with wild-type  UGT1A1 .    Conclusions  Irinotecan chemotherapy might be beneficial in patients with cervical cancer,  UGT1A1  polymorphisms, and ≤ 1 metastatic lymph nodes.

bmc cancer

UGT1A1 polymorphism has a prognostic effect in patients with stage IB or II uterine cervical cancer and one or no metastatic pelvic nodes receiving irinotecan chemotherapy: a retrospective study